[1] |
刘露, 崔馨月, 张宇晶, 等. 成人数据外推至儿科人群探讨[J]. 中国医疗器械杂志, 2019, 43(5): 375-378.
|
[2] |
沈晓明, 王卫平. 儿科学[M]. 第7版. 北京: 人民卫生出版社, 2008.
|
[3] |
Food and Drug Administration. Premarket assessment of pediatric medical devices[EB/OL]. [2024-04-02]. https://www.fda.gov/media/73510/download.
|
[4] |
程云, 张宏. FDA对儿科医疗器械的上市前评价[J]. 首都医药, 2010, 17(20): 8-9.
|
[5] |
中华人民共和国国务院. 医疗器械监督管理条例[国令第739号][EB/OL]. [2024-06-07]. https://www.nmpa.gov.cn/xxgk/fgwj/flxzhfg/20210319202057136.html.
|
[6] |
国家药品监督管理局. 医疗器械优先审批程序[EB/OL]. [2024-06-07]. https://www.cmde.org.cn//flfg/fgwj/ggtg/20220110111838158.html.
|
[7] |
国家药品监督管理局. 用于罕见病防治医疗器械注册审查指导原则[EB/OL]. [2024-06-07]. https://www.cmde.org.cn//flfg/zdyz/zdyzwbk/20181026111100309.html.
|
[8] |
国家药品监督管理局. 医疗器械附条件批准上市指导原则[EB/OL]. [2024-06-07]. https://www.cmde.org.cn//flfg/zdyz/zdyzwbk/20191227092950209.html.
|
[9] |
国家药品监督管理局. 超声多普勒胎儿监护仪注册技术审查指导原则(2017年修订版) [EB/OL]. [2024-06-07]. https://www.cmde.org.cn//flfg/zdyz/zdyzwbk/20180206104300996.html.
|
[10] |
国家药品监督管理局. 含儿科应用的医用诊断X射线设备注册审查指导原则(2021年第104号) [EB/OL]. [2024-06-07]. https://www.cmde.org.cn//flfg/zdyz/zdyzwbk/20211229091445786.html.
|
[11] |
国家药品监督管理局. 新生儿蓝光治疗仪注册审查指导原则(2021年第104号) [EB/OL]. [2024-06-07]. https://www.cmde.org.cn//flfg/zdyz/zdyzwbk/20211229091652336.html.
|
[12] |
Food and Drug Administration. Providing information about pediatric uses of medical devices[EB/OL]. [2024-06-07]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-information-about-pediatric-uses-medical-devices.
|
[13] |
Food and Drug Administration. Leveraging existing clinical data for extrapolation to pediatric uses of medical devices[EB/OL]. [2024-06-07]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/leveraging-existing-clinical-data-extrapolation-pediatric-uses-medical-devices.
|
[14] |
Food and Drug Administration. Ethical considerations for clinical investigations of medical products involving children[EB/OL]. [2024-06-07]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ethical-considerations-clinical-investigations-medical-products-involving-children.
|
[15] |
Food and Drug Administration. Considerations for long-term clinical neurodevelopmental safety studies in neonatal product development[EB/OL]. [2024-06-07]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-long-term-clinical-neurodevelopmental-safety-studies-neonatal-product-development.
|
[16] |
许淑红, 张绮, 张林琦, 等. 探讨我国儿科用药的发展现状及政策层面的思考[J]. 中国临床药理学杂志, 2020, 36(12): 1760-1767.
|
[17] |
程金莲, 谭刚, 赵秀丽, 等. 儿科人群临床试验中对受试者疼痛管理的伦理考虑[J]. 药物评价研究, 2021, 44(6): 1201-1206.
|
[18] |
国家药品监督管理局. 儿科人群药物临床试验技术指导原则[EB/OL]. [2024-06-07]. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=e20e9bd309366a800d3b0cda9f2d9359.
|
[19] |
王晓敏, 虢毅, 袁秀洪, 等. 儿科人群临床研究中"同意"的伦理探讨及对策[J]. 中国医学伦理学, 2018, 31(11): 1403-1407.
|
[20] |
国家药品监督管理局. 真实世界数据用于医疗器械临床评价技术指导原则(试行)(2020年第77号)[EB/OL]. [2024-06-07]. https://www.cmde.org.cn//flfg/zdyz/zdyzwbk/20201126102802881.html.
|
[21] |
国家药品监督管理局. 接受医疗器械境外临床试验数据技术指导原则[EB/OL]. [2024-06-07]. https://www.cmde.org.cn//flfg/zdyz/zdyzwbk/20180206135100162.html.
|